Last Week Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings

May 17, 2018 - By Marcos Kline

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

A total of 5 analysts rate Celldex (NASDAQ:CLDX) as follows: 1 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 20% are bullish. (NASDAQ:CLDX) has 5 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was downgraded by Cowen & Co on Monday, April 16. On Thursday, March 8 the firm has “Market Perform” rating by Leerink Swann given. The company rating was maintained by Cantor Fitzgerald on Tuesday, April 17. On Wednesday, December 6 the stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by WBB Securities. On Thursday, March 8 Jefferies maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) with “Hold” rating. Listed here are Celldex Therapeutics, Inc. (NASDAQ:CLDX) PTs and latest ratings.

17/04/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $9 New Target: $3 Maintain
16/04/2018 Broker: Cowen & Co Rating: Hold Downgrade
08/03/2018 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $4 New Target: $3 Maintain
06/12/2017 Broker: WBB Securities Rating: Buy New Target: $10.0 Maintain

Ticker’s shares touched $0.6902 during the last trading session after 1.02% change.Currently Celldex Therapeutics, Inc. is downtrending after 30.36% change in last May 17, 2017. CLDX has also 812,203 shares volume. CLDX underperformed the S&P 500 by 41.91%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The firm is valued at $98.97 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Last it reported negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Another two news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were briefly released by: on April 19, 2018 with title “Celldex Nearly Back To Square One”. The other‘s article was titled “Celldex Provides Corporate Update and Reports First Quarter 2018 Results” and released on May 10, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.